Adverse reactions : תופעות לוואי

Adverse reactions
Dose limiting toxicities of therapy are myelosuppression and cardiotoxicity. Other reactions reported are:

Infections and infestations: infection, sepsis/septicemia

Neoplasms benign and malignant: acute lymphocytic leukemia, acute myelogenous leukemia 
Blood and lymphatic system disorders: leukopenia, neutropenia, anemia, thrombocytopenia 

8
Immune system disorders: anaphylaxis

Metabolism and nutrition disorders: anorexia, dehydration, hyperuricemia 
Eye disorders: conjunctivitis/keratitis, lacrimation

Cardiac disorders: cardiotoxicity (see warnings), sinus tachycardia, tachyarrhythmias, atrioventricular and bundle branch block, congestive heart failure

Vascular disorders: hemorrhage, hot flashes, phlebitis, thrombophlebitis, phlebosclerosis, thromboembolism, shock

Gastrointestinal disorders: nausea/vomiting, mucositis/stomatitis, hyperpigmentation of oral mucosa, esophagitis, abdominal pain, gastric erosions, gastrointestinal tract bleeding, ulceration and necrosis of colon, diarrhea, colitis

Skin and subcutaneous tissue disorders: alopecia, local toxicity, rash/itch, skin changes, skin and nail hyperpigmentation, photosensitivity, hypersensitivity to irradiated skin (‘radiation recall reaction’), urticaria, acral erythema, palmar plantar erythrodysaesthesia.

Renal and urinary disorders: red coloration of urine for 1 to 2 days after administration 
Reproductive system and breast disorders: amenorrhea, oligospermia, azoospermia 
General disorders and administration site conditions: malaise/asthenia, fever, chills. A case of apparent cross sensitivity to lincomycin has been reported.

Investigations: ECG abnormalities, asymptomatic reductions in left ventricular ejection fraction, changes in transaminase levels

Local: Severe cellulitis, vesication and tissue necrosis will occur if extravasation of doxorubicin occurs during administration. Erythematous streaking along the vein proximal to the site of injection had been reported (See Dosage and administration).

Adverse Reactions in Patients with Early Breast Cancer Receiving Doxorubicin-Containing Adjuvant Therapy: Safety data were collected from approximately 2300 women who participated in a randomized, open-label trial (NSABP B-15) evaluating the use of AC versus CMF in the treatment of early breast cancer involving axillary lymph nodes. The most relevant adverse events reported in this study were consistent with the safety adverse event profile for doxorubicin. Additional adverse events include:

Investigations: weight gain.